1. Most Discussed
  2. Gainers & Losers
ACL 0.9¢

Australian article

  1. caketin

    5,040 Posts.
    57
    Thanks to benthonic at tenbagsfull;


    Biotech Alchemia to sell off assets, return capital to shareholders
    The Australian
    CANCER drug maker Alchemia $ACL will look to sell its assets and return capital to shareholders as another Australian biotech bites the dust. The sale process follows a strategic review by the company, in dire straits since announcing the failure of the Phase III trial of its colorectal cancer drug in October.
    Shares in the Brisbane-based company fell again yesterday on news of the sale process, diving 17 per cent, or 1.5c, to close at 7.5c. This is a far cry from the 62c they were trading at in October before the company announced the drug trial had failed to meet key hurdles required by the US Food and Drug Administration.
    The announcement of the poor results came just weeks after the company’s chief scientist was named Telstra’s Victorian Business Woman of the Year for 2014. In the months since, Alchemia chief executive Thomas Liquard has left the company, with former CEO Tracie Ramsdale taking the helm.
    Alchemia is now headed the way of ASX-listed biotechs QRX Pharma and Acrux, both in the process of selling assets after separate poor trial results in 2014.
    Alchemia owns technology platform HyACT, which helps cancer-fighting drugs target tumours more effectively; fondaparinux sodium, an FDA-approved antithrombotic sold by Dr Reddy’s that generates most of the company’s revenue; a drug discovery platform; and an oncology research business.
    Ms Ramsdale yesterday said the company was targeting paying a dividend to shareholders in the second half of calendar 2015 and would pay out further dividends generated by revenue from fondaparinux, less the costs of running the overall business.
    “Given the substantial tax losses that Alchemia has amassed, it is expected that these future dividends will not have any franking credits attached,” Ms Ramsdale said.
    Morgans analyst Scott Power expected the fondaparinux revenue stream to be worth between 11c and 17c a share. “This is a sensible outcome,” he said.

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.